Patient Note — 163605

progress_notes_163605_1_deid.txt

← Back to all patients Run PA Decision for this patient →

Demographics & Encounter

Patient ID163605 (PHI redacted)
Age / Gender63 / Male
Date of Service2026-04-21
ProviderNone
FacilityPOTOMAC UROLOGY CENTER - Manassas
PayerAnthem
Reason1. Path review 2 week fu.

Diagnoses

C61 Malignant neoplasm of prostate

Medications

Losartan Potassium levoFLOXacin Medication List reviewed and reconciled with the patient Progress Note: [PROVIDER_NAME], MD 04/21/2026 Note generated by eClinicalWorks EMR/PM Software (www.eClinicalWorks.com) Generated for Printing/Faxing/eTransmitting on: 04/21/2026 02:39 PM EDT 1/4 4/21/26, 11:39 AM Print Preview [PATIENT_NAME] DOB: [DOB] (63 yo M) Acc No. [ACCOUNT_ID] DOS: 04/21/2026

Past Medical History

  • CAD
  • Hypertension
  • Prostate Cancer

Vitals

RR 20.0
HR 102.0
BP 138/92
BMI 25.8
WEIGHT 185 lbs
HEIGHT_IN 71.0

Clinical Summary (HPI)

Prostate Cancer (localized): 62 yM with 3+3=6 prostate cancer presents today for path review 2 week f/u. He denies any current urinary issues. No other ED or ejaculatory issues. No UTIs or GH. No kidney stones. Initial diagnosis 3/2023 Prostate Bx (Aug 2024): Benign - - - - - - - - - - - - - - The patient's previous work-up history is listed below: TP MRI fusion PNBx (04/2026): P4 lesion R PZPL mid gland corresponding to templated biopsy locations #3/4. Path: Gleason 4+3=7 RPL#1 (80%), Gleason 3+4=7 RPL#2 (80%), R PZw#1 (10%), Lesion 1A (40%), 1B (40%), 1C (30%), 1D (60%). Gleason 3+3=6 LPL#2 (1%) (reviewed and interpreted) PSA: 8.1 (02/2026), 9.35 (11/2025), 9.13 (08/2025), 6.73 (02/2025), 5.8 (Jan 2024), 5.23 (Jul'23), 6.7 (2/2023), 5.79 (Jan 2023); 6.714 (Oct 2022); 2.85 (Dec 2017). pMRI (11/2025): 54cc, PI-RADS 5 -1cm lesion in right posteriolateral peripheral zone. Transrectal US guided PNBx (non-fusion) (8/2024): Negative. pMRI (12/2023): Vol: 44g, PIRADS 5/5; similar appearance of right mid gland PZ lesion 1.5 broadly abutting adjacent capsule without EPE Fusion PNbx Path (Mar 2023): 1 core Gleason 3+3=6 (RLA less than 5%), ASAP (ROI 1, 1/3 cores). Decipher (Mar'23): 0.51 4k: 18.6 (Jan 2023) pMRI (Feb 2023): Prostate volume 44; PIRASD 5 lesion 1.5 cm right mid gland PZ The patient states he has a history of hemorrhoids. CBC: 96.7 (MCV (Oct 2022) FamHx: Prostate Cancer-Father. Family history Prostate cancer? Yes Family member father

Raw Note (de-identified preview)

4/21/26, 11:39 AM Print Preview [PATIENT_NAME] DOB: [DOB] (63 yo M) Acc No. [ACCOUNT_ID] DOS: 04/21/2026 [PATIENT_NAME] 63 Y old Male, DOB: [DOB] Account: [ACCOUNT_ID]: 163605 [ADDRESS] Home: [PHONE] Guarantor: [GUARANTOR_NAME] Insurance: Anthem BCBS FEP PCP: [PROVIDER_NAME] Referring: [PROVIDER_NAME] Appointment Facility: POTOMAC UROLOGY CENTER - Manassas Structured Data: How did you hear about us? : Primary Care Physician; Patient's temperature : 96.6; : 03/21/2023 04/21/2026 Prostate bx fu: ASEEM MALHOTRA, MD Reason for Appointment 1. Path review 2 week fu. History of Present Illness Prostate Cancer (localized): 62 yM with 3+3=6 prostate cancer presents today for path review 2 week f/u. He denies any current urinary issues. No other ED or ejaculatory issues. No UTIs or GH. No kidney stones. Initial diagnosis 3/2023 Prostate Bx (Aug 2024): Benign - - - - - - - - - - - - - - The patient's previous work-up history is listed below: TP MRI fusion PNBx (04/2026): P4 lesion R PZPL mid gland corresponding to templated biopsy locations #3/4. Path: Gleason 4+3=7 RPL#1 (80%), Gleason 3+4=7 RPL#2 (80%), R PZw#1 (10%), Lesion 1A (40%), 1B (40%), 1C (30%), 1D (60%). Gleason 3+3=6 LPL#2 (1%) (reviewed and interpreted) PSA: 8.1 (02/2026), 9.35 (11/2025), 9.13 (08/2025), 6.73 (02/2025), 5.8 (Jan 2024), 5.23 (Jul'23), 6.7 (2/2023), 5.79 (Jan 2023); 6.714 (Oct 2022); 2.85 (Dec 2017). pMRI (11/2025): 54cc, PI-RADS 5 -1cm lesion in right posteriolateral peripheral zone. Transrectal US guided PNBx (non-fusion) (8/2024): Negative. pMRI (12/2023): Vol: 44g, PIRADS 5/5; similar appearance of right mid gland PZ lesion 1.5 broadly abutting adjacent capsule without EPE Fusion PNbx Path (Mar 2023): 1 core Gleason 3+3=6 (RLA less than 5%), ASAP (ROI 1, 1/3 cores). Decipher (Mar'23): 0.51 4k: 18.6 (Jan 2023) pMRI (Feb 2023): Prostate volume 44; PIRASD 5 lesion 1.5 cm right mid gland PZ The patient states he has a history of hemorrhoids. CBC: 96.7 (MCV (Oct 2022) FamHx: Prostate Cancer-Father. Family history Prostate cancer? Yes Family member father Current Medications Taking Losartan Potassium 100 MG Tablet 1 tablet Orally Once a day levoFLOXacin 500 MG Tablet 1 tablet Orally one time, take the morning of your biopsy procedure Medication List reviewed and reconciled with the patient Progress Note: [PROVIDER_NAME], MD 04/21/2026 Note generated by eClinicalWorks EMR/PM Software (www.eClinicalWorks.com) Generated for Printing/Faxing/eTransmitting on: 04/21/2026 02:39 PM EDT 1/4 4/21/26, 11:39 AM Print Preview [PATIENT_NAME] DOB: [DOB] (63 yo M) Acc No. [ACCOUNT_ID] DOS: 04/21/2026 Past Medical History CAD. Hypertension. Prostate Cancer. Surgical History circumcision 1963 Family History Father: deceased, diagnosed with Malignant neoplasm of prostate Mother: alive 81 yrs prostate cancer. Social History Smoking: no Recreational drug use: no. Exercise: no. Caffeine: yes, frequency:. Alcohol: socially Type: , Frequency: ,Years: , Determination:. Sexually active: yes. Tobacco Contr